SURESHOT FUTURE & MCX EXPERT(LEARNING TECHNO.)💣💲💲💸👇👇💵💴💴

Dips on buy

Dips on buy

Index wins Sell On rise

Single lot Hegde

Hegde Fund stregey Running BTSt Dosto

Ofss up

Alkem sell on rise

IT up

Mphasis Ltim dips on buy

Asian paints dips on buy

Indigo dips on buy

BIOCON INVESTOR PRESENTATION HIGHLIGHTS 💊🌍 • Integrated Generics & Biosimilars business model creating a unified biopharma entity with a stronger balance sheet and improved leverage metrics • Focused on delivering affordable healthcare products and differentiated services across global markets FINANCIAL HIGHLIGHTS 💰 • Improved debt maturity profile through acquisition refinancing and QIP-led redemption of structured instruments • Annual interest savings of ~₹300 Cr expected • Net Debt/EBITDA reduced to 2.7x in FY26 from 4.3x in FY23 • EBITDA growth and margin expansion expected from new product launches and integration synergies CAPEX & MANUFACTURING 🏭 • Major capacity expansion and infrastructure investments largely completed • Existing capacities positioned to support growth for the next 5+ years • Future CapEx expected to be funded through internal cash accruals PRODUCT PORTFOLIO 🚀 • Biotherapeutics contributed 60% of FY26 revenue • Generics contributed 18% of FY26 revenue • Portfolio includes 30+ biosimilars and 3 GLP-1 assets targeting a $200B+ market opportunity • Focused on high-growth segments including Oncology, Immunology and Diabesity GLOBAL REACH 🌎 • Presence across major global markets with a broad partner network • Served over 21 million patients across 120+ countries in FY25 SYNGENE (CRDMO BUSINESS) 🔬 • Well-positioned to benefit from global outsourcing trends • China+1 strategy continues to create growth opportunities • Strong capabilities across research, development and manufacturing services LONG-TERM OPPORTUNITY 📈 • Positioned to benefit from the rising global burden of non-communicable diseases including Cancer, Diabetes and Autoimmune disorders • Management sees significant growth potential through biosimilars, GLP-1 therapies and global healthcare access expansion.

🇮🇳 Rupee & Bond Market Weekly Focus ✅ RBI Policy in Focus: RBI policy decision due on June 5. Reuters poll expects repo rate to remain unchanged at 5.25%. ✅ Rupee Update: INR closed near 95/$, supported by RBI intervention, posting its best weekly gain since late March. ✅ Key Risk: Iran war and high crude prices remain major concerns for India’s inflation, growth, rupee and bond yields. ✅ Bond Market: 10-year benchmark yield ended near 7.00%. Traders expect range of 6.94%–7.06% this week. ✅ Oil Impact: Brent crude eased last week but still remains sharply above pre-war levels, keeping pressure on India’s external position. ✅ Important Data Ahead: • Manufacturing PMI – June 1 • Services PMI – June 3 • RBI Policy – June 5 • GDP Growth Data – June 5, Reuters poll: 7.3% Market View: Rupee and bonds may stay volatile ahead of RBI policy, GDP data, crude movement and global risk sentiment.